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new era of the Hellenic Journal of Cardiology in
Elsevier groupSince the identification of the left ventricle as the chamber
responsible for the systematic circulation, physicians
(especially cardiologists) have investigated left ventricle
function to diagnose and treat most cardiac abnormal-
ities.1,2 Over the years, it has become apparent that sys-
tolic function is only one aspect of left ventricle
performance. The heart compensates to maintain meta-
bolic and tissue requirements when adequate systolic
function firmly and appropriately interacts with diastolic
function, valvular competence, coronary arteries patency,
large artery compliance, and appropriate electrical stimu-
lation of the myocardium.
To this point, the interaction between mitral valve pa-
thology, as defined by imaging techniques, and left
ventricle volume, myocardial contractility, and other left
ventricle hemodynamics is highlighted and comprehen-
sively explained in an outstanding review article by Bou-
doulas et al. in this issue of Hellenic Journal of Cardiology.3
The strength of the inter-dependence is further under-
scored, as symptoms of severity in these patients cannot
only be explained by the amount or percentage of forward
and backward stroke volume but also by neuroendocrine
dysfunction. Finally, these shared mechanisms result in left
atrial/left ventricle dysfunction and in the transmission of
left atrial pressure in the pulmonary circulation.
Likewise, the complex interrelationship between the left
ventricle function and the diverse components of myocar-
dial performance is emphasized in an original article by
Kattel et al. published in this issue of Hellenic Journal of
Cardiology.4 In this article, the authors, motivated by the
high prevalence and morbidity of heart failure with pres-
ervation of ejection fraction5 and the limited understanding
of its pathophysiological background,6 studied the impact ofPeer review under responsibility of Hellenic Cardiological
Society.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).left ventricle hypertrophy in the progression of mild to
moderate left ventricle diastolic dysfunction. Based on
simple echocardiographic techniques and not on advanced
modalities, which have not been completely implemented
in clinical practice,7 these researchers documented the
strong relationship of left ventricle hypertrophy with a
worsened global and diastolic left ventricle function, which
is a finding with potential etiological implications.
Nevertheless, the most common and well-understood
entity is ischemic myocardial dysfunction which may be
caused either by chronic ischemia or after an acute coronary
syndrome.8e10 However, the prognosis and clinical course of
ischemic heart failure is determined by a multiplicity of
mechanisms and by several comorbidities which are not
completely relevant to ischemia per se. From this point of
view, Savic L. et al. performed a prospective study in pa-
tients with STEMI, and they revealed that the mechanism by
which chronic kidney disease interacts with other comor-
bidities, and the risk factors that determine prognosis in this
high risk population is different among men and women.11
These findings are discussed in an editorial by Lazaros G
et al.12 in which the poor outcome in patients with renal
dysfunction and acute coronary events is attributed not only
to gender but to a variety of mechanisms, including high
prevalence of risk factors, greater risk of contrast induced
nephropathy, and higher risk of bleeding.13
As the identification of high risk patients after an index
event cannot make a substantial contribution to the pop-
ulation level, the interest of the new era of cardiovascular
medicine has shifted from the vulnerable plaque hypothesis
to the vulnerable patient concept.14 In this new era, effi-
cient modification of risk factor profile and, especially, of
dyslipidemia, can be achieved by Proprotein Convertase
Subtilisin/Kexin type 9 (PCSK9) inhibitors, reducing LDL
levels substantially and eventually reduce the incidence of
cardiovascular events and ischemic left ventricle dysfunc-
tion15,16 in cases where statins are insufficient orElsevier B.V. This is an open access article under the CC BY-NC-ND
72 Editor’s pageintolerant. However, as Rallidis et al.17 indicated in this
issue of Hellenic Journal of Cardiology, despite the safety
profile of these agents, we must be cautious because the
long-term safety profile has not been established to date,
and questions have been raised regarding cognitive func-
tion and very low LDL cholesterol levels. Despite consid-
erations for the safety profile of PCSK9 inhibitors, this
revolutionized class of drugs is here to stay and is likely to
expand and to open up new horizons.
To this point and with the intention of expanding and
internationalizing the impact of Hellenic Journal of Cardi-
ology, as I promised several months ago, I want to announce
the beginning of a new era for the official Journal of Hellenic
Cardiological Society. From this issue forward, the Hellenic
Journal of Cardiology will be published and hosted by
Elsevier, one of themost important publishers in themedical
field. This cooperation will most likely serve to increase the
impact and readability of the journal in the international
audience and may mark a new period for both the Journal
and for the Hellenic Scientific Cardiological Society.
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